Zydus, Sunshine to set up $20 million pharma JV in Sri LankaIndian pharmaceutical giant Zydus Lifesciences has partnered with Sri Lanka's Sunshine Healthcare Lanka to establish a new manufacturing fa...
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
West Asia crisis eases, but peace could elude consumers for nowConsumers in India will not experience immediate price drops for daily essentials and home appliances. Manufacturers are holding onto raw m...
Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...
India’s consumer demand remains resilient despite Iran war, inflation pressures; FMCG firms stay cautiously optimisticDespite geopolitical turmoil and inflation, domestic consumption of essentials and personal care products remains resilient. Company execut...
From Tata to tech giants, Indian companies tighten grip on UK economyIndian businesses are significantly expanding their UK presence, with company numbers soaring by nearly 60% and combined revenues exceeding...
Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other detailsZydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. Thi...
Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
Zydus Biologics’ Ahmedabad injectable facility gets 7 observations in USFDA inspectionZydus Lifesciences has made headlines as its Zydus Biologics injectable plant in Ahmedabad underwent a USFDA inspection between April 27 an...
Hope to start supply of ZyCoV-D vaccine by mid to end September: Zydus Group MD"Post the emergency use authorisation, now we will work closely with the regulatory authorities to work on the pricing and modality of deli...
Maruti Suzuki sets up multi-specialty hospital at Sitapur in GujaratManaged and operated by Ramanbhai Foundation, the CSR arm of Zydus Group, the hospital is also assisting in taking care of Covid-19 patient...
Zydus ties up with US-based research centre NIAD to develop vaccineThe Group employs over 16,500 people worldwide, including over 1,600 scientists in R&D. Cadila Healthcare is part of Zydus Group.
Zydus launches diabetes treatment drug LipaglynPharmaceutical entity Zydus group on Monday said it has launched Lipaglyn, its patented new drug for treatment of diabetes.
- Cadila Healthcare Q3 net dips by 4.4%, sales rise 20%
Cadila Healthcare, the flagship company of Zydus group, has suffered a 4.4% drop in its third quarter net profit on account of forex losses.